Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Amphastar Pharmaceuticals, Inc. (AMPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $1.13M, a 0.26% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $11.91M, a 11.54% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was $15.00K, a 400.00% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $88.00K, a 20.72% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $11.92M, a 21.38% increase from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $9.82M, a 10.44% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $8.89M, a 8.76% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $8.17M, a 0.04% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.13M 10-Q · filed 2026-08-06 | $13.04M 10-Q · filed 2026-08-06 | $13.06M derived: sum of 3 quarters · filed 2026-08-06 | $13.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $11.91M 10-Q · filed 2026-05-07 | $11.93M derived: sum of 2 quarters · filed 2026-05-07 | $12.01M derived: sum of 3 quarters · filed 2026-05-07 | $13.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $103.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.24M derived: sum of 3 quarters · filed 2026-08-06 | $11.92M 10-K · filed 2026-02-26 |
| 2025-09-30 | $88.00K 10-Q · filed 2025-11-06 | $1.22M derived: sum of 2 quarters · filed 2026-08-06 | $11.90M 10-Q · filed 2025-11-06 | $11.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.14M 10-Q · filed 2026-08-06 | $11.81M 10-Q · filed 2026-08-06 | $11.82M derived: sum of 3 quarters · filed 2026-08-06 | $11.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $10.68M 10-Q · filed 2026-05-07 | $10.68M derived: sum of 2 quarters · filed 2026-05-07 | $10.79M derived: sum of 3 quarters · filed 2026-05-07 | $11.83M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $114.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.16M derived: sum of 3 quarters · filed 2026-02-26 | $9.82M 10-K · filed 2026-02-26 |
| 2024-09-30 | $111.00K 10-Q · filed 2025-11-06 | $1.15M derived: sum of 2 quarters · filed 2025-11-06 | $9.81M 10-Q · filed 2025-11-06 | $9.82M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.04M 10-Q · filed 2025-08-07 | $9.70M 10-Q · filed 2025-08-07 | $9.71M derived: sum of 3 quarters · filed 2026-02-26 | $9.87M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $8.66M 10-Q · filed 2025-05-08 | $8.67M derived: sum of 2 quarters · filed 2026-02-26 | $8.83M derived: sum of 3 quarters · filed 2026-02-26 | $9.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $170.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.31M derived: sum of 3 quarters · filed 2026-02-26 | $8.89M 10-K · filed 2026-02-26 |
| 2023-09-30 | $167.00K 10-Q · filed 2024-11-07 | $1.30M derived: sum of 2 quarters · filed 2024-11-07 | $8.89M 10-Q · filed 2024-11-07 | $8.90M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.14M 10-Q · filed 2024-08-09 | $8.72M 10-Q · filed 2024-08-09 | $8.74M derived: sum of 3 quarters · filed 2025-03-03 | $8.90M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $7.58M 10-Q · filed 2024-05-10 | $7.60M derived: sum of 2 quarters · filed 2025-03-03 | $7.77M derived: sum of 3 quarters · filed 2025-03-03 | $8.77M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $184.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.19M derived: sum of 3 quarters · filed 2025-03-03 | $8.17M 10-K · filed 2025-03-03 |
| 2022-09-30 | $167.00K 10-Q · filed 2023-11-08 | $1.17M derived: sum of 2 quarters · filed 2023-11-08 | $8.16M 10-Q · filed 2023-11-08 | $8.17M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $1.00M 10-Q · filed 2023-08-09 | $7.99M 10-Q · filed 2023-08-09 | $8.01M derived: sum of 3 quarters · filed 2024-02-29 | $8.12M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $6.99M 10-Q · filed 2023-05-09 | $7.00M derived: sum of 2 quarters · filed 2024-02-29 | $7.11M derived: sum of 3 quarters · filed 2024-02-29 | $8.39M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $127.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.41M derived: sum of 3 quarters · filed 2024-02-29 | $8.18M 10-K · filed 2024-02-29 |
| 2021-09-30 | $112.00K 10-Q · filed 2022-11-08 | $1.39M derived: sum of 2 quarters · filed 2022-11-08 | $8.16M 10-Q · filed 2022-11-08 | $8.18M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $1.28M 10-Q · filed 2022-08-09 | $8.05M 10-Q · filed 2022-08-09 | $8.06M derived: sum of 3 quarters · filed 2023-03-01 | $8.18M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $6.77M 10-Q · filed 2022-05-10 | $6.79M derived: sum of 2 quarters · filed 2023-03-01 | $6.91M derived: sum of 3 quarters · filed 2023-03-01 | $9.32M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $134.00K derived: sum of 2 quarters · filed 2023-03-01 | $2.54M derived: sum of 3 quarters · filed 2023-03-01 | $9.98M 10-K · filed 2023-03-01 |
| 2020-09-30 | $121.00K 10-Q · filed 2021-11-09 | $2.53M derived: sum of 2 quarters · filed 2021-11-09 | $9.96M 10-Q · filed 2021-11-09 | $9.99M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $2.41M 10-Q · filed 2021-08-09 | $9.84M 10-Q · filed 2021-08-09 | $9.87M derived: sum of 3 quarters · filed 2022-03-11 | $9.95M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $7.43M 10-Q · filed 2021-05-07 | $7.46M derived: sum of 2 quarters · filed 2022-03-11 | $7.54M derived: sum of 3 quarters · filed 2022-03-11 | $7.93M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $111.00K derived: sum of 2 quarters · filed 2022-03-11 | $499.00K derived: sum of 3 quarters · filed 2022-03-11 | $7.61M 10-K · filed 2022-03-11 |
| 2019-09-30 | $85.00K 10-Q · filed 2020-11-06 | $473.00K derived: sum of 2 quarters · filed 2020-11-06 | $7.59M 10-Q · filed 2020-11-06 | $7.60M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $388.00K 10-Q · filed 2020-08-07 | $7.50M 10-Q · filed 2020-08-07 | $7.51M derived: sum of 3 quarters · filed 2021-03-15 | $7.61M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $7.12M 10-Q · filed 2020-05-11 | $7.12M derived: sum of 2 quarters · filed 2021-03-15 | $7.22M derived: sum of 3 quarters · filed 2021-03-15 | $8.60M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $102.00K derived: sum of 2 quarters · filed 2021-03-15 | $1.49M derived: sum of 3 quarters · filed 2021-03-15 | $7.97M 10-K · filed 2021-03-15 |
| 2018-09-30 | $93.00K 10-Q · filed 2019-11-08 | $1.48M derived: sum of 2 quarters · filed 2019-11-08 | $7.96M 10-Q · filed 2019-11-08 | $8.16M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $1.38M 10-Q · filed 2019-08-09 | $7.79M 10-Q · filed 2019-08-09 | $8.07M derived: sum of 3 quarters · filed 2020-03-16 | $8.85M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $6.41M 10-Q · filed 2019-05-10 | $6.69M derived: sum of 2 quarters · filed 2020-03-16 | $7.46M derived: sum of 3 quarters · filed 2020-03-16 | $8.89M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | $279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.06M derived: sum of 2 quarters · filed 2020-03-16 | $2.48M derived: sum of 3 quarters · filed 2020-03-16 | $7.26M 10-K · filed 2020-03-16 |
| 2017-09-30 | $779.00K 10-Q · filed 2018-11-09 | $2.20M derived: sum of 2 quarters · filed 2018-11-09 | $6.98M 10-Q · filed 2018-11-09 | $7.69M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $1.42M 10-Q · filed 2018-08-09 | $6.21M 10-Q · filed 2018-08-09 | $6.91M derived: sum of 3 quarters · filed 2019-03-15 | $9.60M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $4.78M 10-Q · filed 2018-05-10 | $5.49M derived: sum of 2 quarters · filed 2019-03-15 | $8.18M derived: sum of 3 quarters · filed 2019-03-15 | $10.18M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $706.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $3.39M derived: sum of 2 quarters · filed 2019-03-15 | $5.39M derived: sum of 3 quarters · filed 2019-03-15 | $8.65M 10-K · filed 2019-03-15 |
| 2016-09-30 | $2.69M 10-Q · filed 2017-11-09 | $4.69M derived: sum of 2 quarters · filed 2017-11-09 | $7.95M 10-Q · filed 2017-11-09 | $9.16M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $2.00M 10-Q · filed 2017-08-09 | $5.26M 10-Q · filed 2017-08-09 | $6.47M derived: sum of 3 quarters · filed 2018-03-14 | $9.36M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $3.26M 10-Q · filed 2017-05-10 | $4.47M derived: sum of 2 quarters · filed 2018-03-14 | $7.36M derived: sum of 3 quarters · filed 2018-03-14 | $8.47M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $4.10M derived: sum of 2 quarters · filed 2018-03-14 | $5.21M derived: sum of 3 quarters · filed 2018-03-14 | $6.63M 10-K · filed 2018-03-14 |
| 2015-09-30 | $2.89M 10-Q · filed 2016-11-09 | $4.00M derived: sum of 2 quarters · filed 2016-11-09 | $5.42M 10-Q · filed 2016-11-09 | $7.51M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $1.11M 10-Q · filed 2016-08-09 | $2.54M 10-Q · filed 2016-08-09 | $4.62M derived: sum of 3 quarters · filed 2017-03-15 | $8.13M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $1.42M 10-Q · filed 2016-05-10 | $3.51M derived: sum of 2 quarters · filed 2017-03-15 | $7.02M derived: sum of 3 quarters · filed 2017-03-15 | $7.31M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $5.59M derived: sum of 2 quarters · filed 2017-03-15 | $5.88M derived: sum of 3 quarters · filed 2017-03-15 | $6.41M 10-K · filed 2017-03-15 |
| 2014-09-30 | $3.51M 10-Q · filed 2015-11-13 | $3.80M derived: sum of 2 quarters · filed 2015-11-13 | $4.32M 10-Q · filed 2015-11-13 | $6.34M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | $290.00K 10-Q · filed 2015-08-13 | $816.00K 10-Q · filed 2015-08-13 | $2.83M derived: sum of 3 quarters · filed 2016-03-15 | $6.03M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | $526.00K 10-Q · filed 2015-05-14 | $2.54M derived: sum of 2 quarters · filed 2016-03-15 | $5.74M derived: sum of 3 quarters · filed 2016-03-15 | $6.04M derived: sum of 4 quarters · filed 2016-03-15 |
| 2013-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $5.21M derived: sum of 2 quarters · filed 2016-03-15 | $5.51M derived: sum of 3 quarters · filed 2016-03-15 | $6.07M 10-K · filed 2016-03-15 |
| 2013-09-30 | $3.20M 10-Q · filed 2014-11-13 | $3.50M derived: sum of 2 quarters · filed 2014-11-13 | $4.06M 10-Q · filed 2014-11-13 | |
| 2013-06-30 | $301.00K 10-Q · filed 2014-08-13 | $855.00K 10-Q · filed 2014-08-13 | ||
| 2012-12-31 | $6.81M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |